News & Presentations

AR-V7 expression in CTCs isolated with TellDx is an independent …

Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223 Read More

Prostate Circulating Tumor Cells Isolated with TellDx Technology Demonstrates Epigenetic …

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer Read More

CTCs isolated with TellDx leveraged to assess sensitivity and potential …

Circulating Tumor Cells Isolated with Unique TellDx Technology May Help Predict Response to Therapy in Patients with Progressive Metastatic Breast Cancer Read More

Interrogation of circulating tumor cells (CTCs) shows downregulation of KEAP1 …

Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma Read More

TellDx CTC System can be leveraged to monitor efficacy of …

Reduction in Circulating Tumor Cells (CTC), Enriched by TellBio Platform, with Novel Dual-Cadherin Antibody (23C6) Results in Significant Metastasis Suppression Read More

Single-cell proteomics can elucidate kinase activity in prostate cancer models …

Circulating Tumor Cell (CTC) Isolation with TellDx Technology Could Inform Personalized Drug Treatment in Prostate Cancer Read More

Rare parallel analyses of directly matched CTCs, utilizing TellBio’s TellDx …

TellBio’s Scientific Founders Publish Very High Concordance between CTCs and ctDNA from Liquid Biopsies in Patients with Breast Cancer Read More

Closes $5 million Series A financing Appoints Pritesh J. Gandhi, …

TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer Read More